ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe
Myovant expects to secure European commercialization partner ahead of anticipated launches
BASEL, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer. The approval is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein.
“Now for the first time, patients in Europe have the ability to rapidly reduce testosterone without hormonal flare in a convenient oral form,” said Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences, Inc. “This approval provides a valuable new treatment option for men with advanced hormone-sensitive prostate cancer in Europe and has the potential to change the standard of care over time.”
“We’ve made significant progress in securing a business partner for the commercialization of ORGOVYX® in Europe. We’ve had interest from multiple parties and anticipate an announcement in the upcoming weeks, in advance of the anticipated launches in European markets,” said David Marek, Chief Executive Officer, Myovant Sciences, Inc.
This approval was supported by data from the Phase 3 HERO study, a randomized, open-label, parallel-group, multinational clinical study designed to evaluate the safety and efficacy of relugolix. The study compared relugolix to leuprolide in over 1,000 men with androgen-sensitive advanced prostate cancer who required at least one year of continuous androgen deprivation therapy. ORGOVYX® received U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with advanced prostate cancer in December 2020.
In the HERO study, ORGOVYX® met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in 96.7% (95% confidence interval [CI]: 94.9-97.9) of men, compared with 88.8% (95% CI: 84.6-91.8) of men receiving leuprolide acetate injections, the current standard of care. ORGOVYX® also achieved several key secondary endpoints compared to leuprolide acetate, including suppression of testosterone to castrate levels at Day 4 and Day 15 (56% versus 0% and 99% versus 12%, respectively) and profound suppression of testosterone (< 20 ng/dL) at Day 15 (78% versus 1%). The most frequent adverse events reported in at least 10% of men in the ORGOVYX® group were hot flush, musculoskeletal pain, fatigue, constipation, and mild to moderate diarrhea. The HERO data were previously presented in an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, with simultaneous publication in The New England Journal of Medicine.
About Prostate Cancer Prostate cancer is a leading cause of death in the European Union with about 65,200 men having died from the disease in 2016. The standardized death rate from prostate cancer stood at 38 deaths per 100,000 male inhabitants according to Eurostat.
Prostate cancer is considered advanced when it has spread or come back after initial treatment and may include biochemical recurrence (rising prostate-specific antigen in the absence of metastatic disease on imaging), locally advanced disease, or metastatic disease. Front-line medical therapy for advanced prostate cancer typically involves androgen deprivation therapy, which reduces testosterone to very low levels, commonly referred to as castrate levels (< 50 ng/dL). Luteinizing hormone-releasing hormone (LHRH) receptor agonists, such as leuprolide acetate, are depot injections and the current standard of care for androgen deprivation therapy. However, LHRH receptor agonists may be associated with mechanism- of-action limitations, including the potentially detrimental initial surge in testosterone levels that can exacerbate clinical symptoms, which is known as clinical or hormonal flare, and delayed testosterone recovery after the drug is discontinued.
About ORGOVYX® (relugolix) ORGOVYX® (relugolix, 120 mg) is indicated in Europe for the treatment of adult patients with advanced hormone-sensitive prostate cancer. As a GnRH antagonist, ORGOVYX® blocks the GnRH receptor and reduces production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer.
About Myovant Sciences Myovant Sciences is a healthcare company focused on redefining care through differentiated solutions in high unmet need areas within women’s health and hormone-sensitive oncology. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to two regulatory approvals by the U.S. Food and Drug Administration (FDA) for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively. The company also has received regulatory approvals by the European Commission (EC) for women with symptomatic uterine fibroids and for men with advanced hormone-sensitive prostate cancer. The company has a supplemental New Drug Application in endometriosis-associated pain pending with the U.S. FDA. Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. Myovant also is developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Myovant Sciences’ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this press release, forward-looking statements include, but are not limited to, all statements reflecting Myovant Sciences’ expectations, including: statements regarding Myovant’s aspiration to redefine care through differentiated solutions in high unmet need areas within women’s health and hormone-sensitive oncology; the expectations for the potential commercialization and launch of ORGOVYX® for adult patients with hormone-sensitive advanced prostate cancer in Europe; Myovant’s expectations regarding partnership opportunities with multiple interested parties for European commercialization of relugolix in advanced hormone-sensitive prostate cancer, including the timing of any potential agreement with a partner by the anticipated launch of ORGOVYX® in European markets; and Myovant’s expectations regarding the potential benefits of ORGOVYX® and its potential to become the new standard of care in advanced hormone-sensitive prostate cancer.
For a further discussion of factors that could materially affect Myovant Sciences’ operations and future prospects or which could cause actual results to differ materially from expectations, see the risks and uncertainties listed in Myovant Sciences’ filings with the United States Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Myovant Sciences’ Quarterly Report on Form 10-Q filed on January 26, 2022, as such risk factors may be amended, supplemented, or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for Myovant Sciences’ management to predict all risk factors, nor can Myovant Sciences assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and, except as required by law, Myovant Sciences undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements.
Myovant Sciences Investor Contact: Uneek Mehra Chief Financial and Business Officer Myovant Sciences, Inc. investors@myovant.com
Myovant Sciences Media Contact: Noelle Cloud Dugan Vice President, Corporate Communications and Public Affairs Myovant Sciences, Inc. media@myovant.com
In the early days of the coronavirus vaccine race, Inovio Pharmaceuticals (NASDAQ: INO) was one of the favorites. One major headwind slowed things down: The U.S. Food and Drug Administration (FDA) placed Inovio's coronavirus vaccine trial on a partial clinical hold in late 2020. Does all of this mean Inovio is in trouble?
The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
The pill has become an increasingly important tool in the nation’s defense against COVID-19 as mask mandates have lifted and people have returned to their non-distanced lives.
Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia. In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.
Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.
Earlier in April, the Marijuana Opportunity Reinvestment and Expungement Act (MORE) was narrowly passed by the United States House of Representatives by a vote of 220-204. Marijuana use was legal until 29 U.S. states banned it between 1916 and 1931.
The city's largest tech employer also said it will be offering counseling from Burlingame-based metal-health service provider Lyra Health.
The progressive brain disorder known as dementia affects several important areas of the brain, which can cause problems with a number of crucial functions. One of them is speech. If you or your loved ones notice these five things about how you're speaking, it might be an indicator of dementia. Here's what they are, and what to do about them. Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Trouble Finding the Rig
Fiber has a lot to offer—it can support your gut health, help you lose weight or and even keep you feeling full for longer. To help you reap the benefits of getting enough fiber each day, these breakfasts include at least 6 grams of fiber per serving. Plus, each recipe focuses on complex carbs, like whole grains, and sticks to heart-healthy levels of saturated fat and sodium for a meal that fits perfectly into a diabetes-friendly routine.
Dr. Anthony Fauci, the nation’s top infectious disease specialist, told The Root today that cases of the deadly Covid-19 virus are slowly rising again across the country and warned that Black Americans could be particularly at risk in the event a more aggressive variant should appear. Fauci spoke with The Root this afternoon where he clarified his own comments about where the nation stood on the status of the pandemic as the country nears the milestone of 1 million deaths from the virus, which o
Bristol mum-of-three Ruth Cookson, 34, lost her own mother in 1996, aged just 41, to breast cancer and is desperate to see her children become adults
SEOUL, South Korea — South Korea has a reputation for world-class medical care. But faith in its hospitals has been shaken by years of complaints about doctors mishandling unconscious patients, including turning them over to unsupervised assistants who perform what are known as “ghost surgeries.” To stem the practice, lawmakers amended the country’s medical laws last year to require cameras in all operating rooms that handle patients under general anesthesia, making South Korea one of the first
Paul Hennessy/SOPA Images/LightRocket via Getty A baby formula shortage has added to the woes of American parents already confronted with the pressures of raising an infant during a pandemic in a country ranked low for family-friendly policies.Media reports have highlighted the plight of mothers, fathers and caregivers across the U.S. who have scrambled to find scarce supplies, or driven long distances to buy formula.But what is behind the shortage? And how can it be prevented from happening aga
"I was in a medically induced coma for six weeks. There were times I was fully conscious, but I couldn't open my eyes, couldn't move a muscle, and couldn't speak. It was terrifying."View Entire Post ›
Public health experts are divided over how many people are getting long COVID-19, a potentially debilitating condition that comes after a patient has recovered from the coronavirus. Ill effects from the condition can include fatigue, pain, neurological issues and even changes in mental health. Initially, public health officials believed that only a small minority of…
Ashley Judd is speaking out about mother Naomi Judd's cause of death — to get ahead of the news.
The Duke of Cambridge has personally delivered a damehood to the home of Deborah James, visiting with her family to honour her campaign to raise awareness of bowel cancer.
Hepatitis C and HIV cost every taxpayer. Preventing new infections isn’t just an issue of health care — it also saves the public money. | Opinion
Podcast host announced on Monday that she has halted cancer treatment and moved into hospice-at-home care